Alzheimer's Disease
Neuro solutions.
Pioneering AI solutions driving breakthroughs in Alzheimer's Disease research and clinical practice.
About Alzheimer's Disease.
Alzheimer's disease, the leading cause of dementia (60-80%), progressively worsens memory, thinking, and behavior, leading to severe cognitive decline and death. It is characterized by beta-amyloid protein accumulation outside neurons and tau protein inside neurons, causing neuron death and brain damage, including inflammation and atrophy. Recently, three anti-amyloid beta (Aβ) immunotherapies have shown increasing benefits in phase 3 clinical trials and begun receiving FDA approval. These therapies are likely to gain wider approval, transforming Alzheimer's disease management.
How to make a difference.
The current breakthrough in the field will soon redefine disease management, raising new scientific challenges for radiologists and neurologists. Recent clinical trial outcomes indicate that, for the first time, anti-amyloid treatment could slow cognitive decline. This breakthrough changes the paradigm of Alzheimer’s treatment and offers hope to patients and families. However, this transformation presents scientific and clinical challenges, requiring implementing a complex treatment plan, particularly in brain imaging monitoring. TheraPanacea leverages state-of-the-art technology to unlock AI-powered solutions that enhance the workflow of R&D teams and clinicians.